NeuSpera Medical is a technology company.
NeuSpera Medical has raised $126.0M across 4 funding rounds.
NeuSpera Medical has raised $126.0M in total across 4 funding rounds.
NeuSpera Medical has raised $126.0M in total across 4 funding rounds.
NeuSpera Medical's investors include Creacion Ventures, Vertex Ventures.
Neuspera Medical is a medtech company developing minimally invasive implantable neurostimulation devices, with its flagship product being the first FDA-approved integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI), a key symptom of overactive bladder (OAB).[1][2][4] The system features an ultra-miniaturized, battery-free implant near the sacral nerve, powered by a discreet external wearable charger, delivering therapy comparable to traditional SNM while eliminating implanted battery risks and complications.[1][3][4] It serves patients, primarily women (affecting 1 in 5 in the U.S.), frustrated by unpredictable UUI episodes that disrupt daily life, offering a patient-centered, less invasive alternative that fits seamlessly into lifestyles.[1][4]
The company solves the problem of ineffective or burdensome OAB treatments by providing accessible, comfortable neuromodulation with directional energy adaptation for deep-body implants, backed by $23 million in Series D funding in 2024 to reach FDA approval, achieved in June 2025.[1][3][4] Growth momentum includes FDA clearance for chronic peripheral nerve pain earlier and full UUI approval, positioning Neuspera for U.S. commercialization amid rising demand for advanced OAB therapies.[3][4]
Neuspera Medical emerged from the vision of Alexander J. Yeh, its founder, Chief Technology Officer, and VP of Research & Development, a medical device innovator focused on transforming millimeter-sized wireless implants into practical tools for patient care.[2] The idea stemmed from advancing directionally adaptive energy systems to power tiny deep-body implants, starting with sacral neuromodulation for UUI.[1][2] Key leadership includes Dave, a 30-year medtech veteran and CEO who scaled Ivantis from early employee to $475 million acquisition by Alcon after FDA approval and global sales; and Steve, a commercial expert who grew Vertos Medical's revenue from $10 million to $80 million before its Stryker acquisition.[2]
Pivotal early traction came via $23 million Series D financing in July 2024, led by Vertex Ventures HC and Treo Ventures, funding through FDA premarket approval.[3] This built on prior FDA clearance for chronic pain, culminating in June 2025 UUI approval—the first for an integrated SNM system—marking a breakthrough from investigational device to market-ready therapy.[3][4]
Neuspera rides the neuromodulation wave in medtech, targeting the growing OAB market where UUI affects 1 in 5 U.S. women, driving demand for less invasive alternatives to drugs or traditional SNM with bulky implants.[1][4] Timing aligns with 2025 FDA approval amid post-pandemic focus on quality-of-life therapies for chronic conditions, fueled by miniaturization advances in wireless power and implants.[1][2][4] Market forces like aging populations, reimbursement expansions, and investor interest (e.g., Series D from medtech VCs) favor discreet, efficacious devices that reduce surgical risks.[3]
The company influences the ecosystem by pioneering iSNM, potentially expanding sacral neuromodulation access and inspiring battery-free platforms for pain, neurology, and beyond, challenging incumbents with patient-preferred form factors.[1][3]
Neuspera is poised for U.S. launch and revenue ramp post-2025 FDA approval, leveraging its validated efficacy to capture OAB share from legacy SNM providers.[4] Trends like AI-optimized stimulation, further miniaturization, and global expansion (building on pain clearance) will shape growth, with platform adaptability opening pipelines for new indications.[1][2] Influence may evolve from UUI disruptor to neuromodulation leader, as team track record suggests scalable adoption and potential acquisition.
This positions Neuspera as a patient-empowering medtech innovator, reclaiming lives from OAB's frustrations through uncompromised, lifestyle-fitting therapy.[1]
NeuSpera Medical has raised $126.0M across 4 funding rounds. Most recently, it raised $23.0M Series D in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $23.0M Series D | Creacion Ventures, Vertex Ventures | |
| Jul 1, 2021 | $65.0M Series C | Creacion Ventures, Vertex Ventures | |
| Feb 1, 2019 | $12.0M Series B | Creacion Ventures, Vertex Ventures | |
| Jan 1, 2018 | $26.0M Series B | Creacion Ventures, Vertex Ventures |